Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
Citius Pharmaceuticals Inc is a biotechnology business based in the US. Citius Pharmaceuticals shares (CTXR) are listed on the NASDAQ and all prices are listed in US Dollars. Citius Pharmaceuticals employs 10 staff and has a market cap (total outstanding shares value) of 0.00.
|Latest market close||$2.03|
|52-week range||$0.87 - $4.56|
|50-day moving average||$2.08|
|200-day moving average||$2.19|
|Wall St. target price||$7.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.28|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-13)||-0.49%|
|1 month (2021-09-22)||-4.69%|
|3 months (2021-07-22)||1.50%|
|6 months (2021-04-22)||12.78%|
|1 year (2020-10-22)||84.55%|
|2 years (2019-10-22)||244.42%|
|3 years (2018-10-22)||26.09%|
|5 years (2016-10-21)||223.76%|
|Gross profit TTM||$0|
|Return on assets TTM||-15.18%|
|Return on equity TTM||-26.76%|
|Market capitalisation||$305.1 million|
TTM: trailing 12 months
There are currently 14.5 million Citius Pharmaceuticals shares held short by investors – that's known as Citius Pharmaceuticals's "short interest". This figure is 0.3% up from 14.4 million last month.
There are a few different ways that this level of interest in shorting Citius Pharmaceuticals shares can be evaluated.
Citius Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Citius Pharmaceuticals shares currently shorted divided by the average quantity of Citius Pharmaceuticals shares traded daily (recently around 2.9 million). Citius Pharmaceuticals's SIR currently stands at 4.96. In other words for every 100,000 Citius Pharmaceuticals shares traded daily on the market, roughly 4960 shares are currently held short.
However Citius Pharmaceuticals's short interest can also be evaluated against the total number of Citius Pharmaceuticals shares, or, against the total number of tradable Citius Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Citius Pharmaceuticals's short interest could be expressed as 0.1% of the outstanding shares (for every 100,000 Citius Pharmaceuticals shares in existence, roughly 100 shares are currently held short) or 0.1082% of the tradable shares (for every 100,000 tradable Citius Pharmaceuticals shares, roughly 108 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Citius Pharmaceuticals.
Find out more about how you can short Citius Pharmaceuticals stock.
We're not expecting Citius Pharmaceuticals to pay a dividend over the next 12 months.
Citius Pharmaceuticals's shares were split on a 1:15 basis on 8 June 2017. So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Citius Pharmaceuticals shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for Citius Pharmaceuticals shares which in turn could have impacted Citius Pharmaceuticals's share price.
Over the last 12 months, Citius Pharmaceuticals's shares have ranged in value from as little as $0.873 up to $4.56. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Citius Pharmaceuticals's is 1.5407. This would suggest that Citius Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Citius Pharmaceuticals, Inc. , a specialty pharmaceutical company, develops and commercializes critical care products targeting medical needs with a focus on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing four proprietary products, including Mino-Lok, an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey. .
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.